Video
Study explores patient-reported outcomes for UGN-102 in NMIBC
Author(s):
“What we did find is that UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating, flatulence, or malaise at the primary trial end point of 3 months,” says Angela M. Stover, PhD.
In this video, Angela M. Stover, PhD, discusses the rationale and notable findings from the Journal of Urology study, “Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer,” for which she served as a study author. Stover is an assistant professor of health policy and management at the University of North Carolina, Chapel Hill.
Related Videos
Related Content
